Navigation Links
Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
Date:10/22/2008

CAMBRIDGE, Mass., Oct. 22 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced new data from early non-clinical studies of Millennium/Takeda-discovered pipeline molecules highlighting novel therapeutic pathways in oncology. MLN4924 data build on the growing body of evidence supporting the importance of the Millennium-discovered Nedd8 Activating Enzyme (NAE) in tumor growth and survival. It is a first-in-class small molecule inhibitor of NAE. Both clinical and non-clinical studies of MLN8237 confirm the importance of inhibiting Aurora A kinase, which is required for cells to proceed through cell division.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080827/NEW076LOGO )

TAK-285 and TAK-593 are receptor tyrosine kinase inhibitors. Non-clinical data suggest their efficacy in affecting the Epidermal Growth Factor Receptor / Human Epidermal Growth Factor Receptor (EGFR/HER) and Vascular Endothelial Growth Factor/Platelet Derived Growth Factor (VEGF/PDGF) pathways, respectively. The data from 21 Millennium abstracts were presented at the 20th EORTC-NCI-AACR* Symposium on "Molecular Targets and Cancer Therapeutics" held October 21 to 24 in Geneva, Switzerland.

"These new data demonstrate the potential of novel pathways and innovative approaches to existing pathways that will further oncology research," said Nancy Simonian, M.D., Chief Medical Officer, Millennium. "Early results such as these demonstrate our oncology expertise in advancing both the current Millennium oncology molecules and those we are integrating into our pipeline from Takeda."

MLN4924

MLN4924 is a first-in-class small molecule inhibitor of NAE, a new target discovered by Millennium scientists. Data from two non-clinical studies showcased at EORTC highlight its potent activity in inducing apoptosis, or programmed cell death, in cultured human tumor cells and human
'/>"/>

SOURCE Millennium: The Takeda Oncology Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
2. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress
5. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
6. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
7. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
8. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
9. Access Pharmaceuticals Presents New Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
10. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
11. Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014  Decision Resources Group finds that while ... specialists are willing to prescribe Durata,s Dalvance (dalbavancin) ... as OPAT, approximately two-thirds of the respondents reported ... hospital inpatients. However, our findings indicate that nearly ... on OPAT following hospital discharge, and most are ...
(Date:7/10/2014)... , July 10, 2014 CVS Caremark Corporation (NYSE: ... directors has approved a quarterly dividend of $0.275 (27.5 cents) ... payable on August 1, 2014, to holders of record on ... CVS Caremark is dedicated to helping people on their ... in the United States . Through the ...
(Date:1/15/2014)... , Jan. 15, 2014 Sono-Tek Corporation (OTC BB: ... ended November 30, 2013, compared to sales of $2,202,000 for ... Once again, this quarter has also shown growth over the ... first quarter of this fiscal year. Markets that experienced sales ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... Study of Zalutumumab in Combination, With Radiotherapy ... COPENHAGEN, June 24 Genmab A/S (OMX: GEN),announced ... zalutumumab,(HuMax-EGFr(TM)) in combination with radiotherapy for the treatment of,advanced ... maximum of 36,patients who are ineligible for platinum based ...
... New Recommendations Address Presurgery and Pediatric Dilemmas, ... evidence-based guidelines,address the prevention and management of ... related to the routine use of,preventive therapies. ... issue of CHEST,the peer-reviewed journal of the ...
Cached Medicine Technology:Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer 2Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer 3Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women 2Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women 3Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women 4
(Date:7/13/2014)... July 13, 2014 Chromatography system ... components from various types of biological samples such ... the sample mixture into two phase, namely mobile ... mobile phase run over the stationary phase, followed ... components that provide the separation of mixture. Chromatography ...
(Date:7/13/2014)... The report “Micronutrient Market by ... (Chelated & Non Chelated), Application Mode (Soil, Foliar, ... and Forecast to 2018” defines and segments the ... forecasting of the global value and volume for ... restraining factors for the global agriculture micronutrients market ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 A Massachusetts ... to the cancer risks associated with power morcellators ( ... their story to federal regulators, as they presented poignant ... Food & Drug Administration (FDA) advisory panel meeting convened ... According to the Rochester Democrat and Chronicle, Dr. Hooman ...
(Date:7/13/2014)... 13, 2014 Recently, 2014QuinceaneraDresses.com, the ... unveiled its new range of gorgeous Quinceanera ... the demand for elegant Quinceanera outfits is huge. ... items. All the company’s newly released dresses are ... are all elegant and vivid. , It ...
(Date:7/13/2014)... noninvasive optical imaging device developed at Cedars-Sinai can ... in the brain and are a classic sign ... investigators conducting a clinical trial in Australia. , ... in an oral presentation at the Alzheimer,s Association ... were invited by conference organizers to participate in ...
Breaking Medicine News(10 mins):Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 2Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3
... 2 Covaris Incorporated today announced the introduction ... technology.Over the past few years, Covaris instruments have ... as a sample preparation step for next generation ... compatible with all next-gen sequencing platforms. This ...
... on Solidifying Interoperability Standards within HIT Solutions to ... April 2 Greenway Medical Technologies ... health record (EHR), practice management and interoperability solution ... and Management Systems Society (HIMSS) and Integrating the ...
... 2 Despite government efforts to address disparities in ... and Ethnic Health Disparities Initiative, there has been very ... death than Caucasians(1).The statistics are alarming:, ... are 1.6 times more likely to have diabetes than ...
... of alcohol-linked deaths are tied to bouts of excessive consumption, ... drinking in the United States is most common among whites, ... $50,000 or more a year, according to a study released ... or more drinks on one occasion. , The U.S. Centers ...
... of regrowing damaged cardiac tissue, experts say, , , THURSDAY, April ... found that the human heart continues to generate new cardiac ... cell production slows with age. , The finding, published ... open a new path for the treatment of heart diseases ...
... Patients with severe heart failure can be bridged to ... heart pump, according to a just-completed study of the ... reported at the 58th annual meeting of the American ... called a left ventricular assist device (LVAD), is the ...
Cached Medicine News:Health News:Covaris Introduces DNA Shearing Service 2Health News:Greenway Medical Technologies Continues to Champion Interoperability Efforts with Extensive Participation in HIMSS' 2009 Interoperability Showcase 2Health News:Greenway Medical Technologies Continues to Champion Interoperability Efforts with Extensive Participation in HIMSS' 2009 Interoperability Showcase 3Health News:Greenway Medical Technologies Continues to Champion Interoperability Efforts with Extensive Participation in HIMSS' 2009 Interoperability Showcase 4Health News:Health Disparities Among Minority Populations Getting Worse 2Health News:Health Disparities Among Minority Populations Getting Worse 3Health News:Typical Binge Drinker Is Young White Male 2Health News:Human Heart Can Make New Cells 2Health News:Human Heart Can Make New Cells 3Health News:Artificial pump effectively backs up failing hearts 2Health News:Artificial pump effectively backs up failing hearts 3
... like all important missions, require ... you to your destination. The ... this dependability. So you can ... intervention and not have to ...
The FLEXI-CUT Directional Debulking System is Abbott Vascular's latest atherectomy catheter designed to enhance performance and ease-of-use....
Tests for protan and deutan defects. Patients must identify numbers or patterns formed in a matrix of small colored dots varying in color and intensity. Two editions available: 38 plate for detailed ...
STAT-CRIT is a rapid, one-step system for measuring hematocrit....
Medicine Products: